ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SNN vs EW // EV/EBITDA & P/E VALUATION

Smith & Nephew SNATS Inc. (NYSE) VS. Edwards Lifesciences Corporation (NYSE) • 15-METRIC TALLY: SNN 2 — EW 9
▲ EV/EBITDA & P/E VALUATION LEADER: SNN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SNN VS. EW) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SNN EW SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 78.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 12.50% -2.60 EW /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 21.0x 35.1x -14.10 SNN /valuation <GO>
Free Cash Flow Yield 2.21% 2.45% -0.24 EW /fcf-yield <GO>
Operating Margin 13.90% 20.80% -6.90 EW /operating-margins <GO>
Net Profit Margin 10.90% 17.70% -6.80 EW /net-margins <GO>
Revenue Growth (YoY) 6.60% 11.50% -4.90 EW /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 12.36 -8.62 EW /balance-sheet <GO>
Piotroski F-Score Quality 8/9 8/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 63.6 65.1 -1.50 EW /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.03 1.08 -0.05 EW /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 47.2x -16.70 SNN /forward-pe <GO>
Enterprise Scale & Market Cap $12.73B $54.44B -$41.70B EW /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SNN REV EW REV SNN GROSS % EW GROSS % SNN FCF EW FCF
FY 2025 — $6.07B — 78.0% — $1.33B
FY 2024 — $5.44B — 79.5% — $289.9M
FY 2023 — $5.01B — — — $670.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SNN // BETA 1.03
EW // BETA 1.08